- Home
- J&J Innovative Medicine
J&J Innovative Medicine
What is asthma?
This chronic inflammatory disease causes flareups that make it difficult to breathe. Learn about the two types of asthma, common triggers and how Johnson & Johnson is developing approaches that may lead to better treatments.
Johnson & Johnson named a 2026 Fortune World’s Most Admired Company
The company made the prestigious list for the 24th consecutive year, thanks to its dedication to innovation and social responsibility, among other criteria.
What is lupus?
Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.
What you need to know about Johnson & Johnson’s fourth-quarter and full-year 2025 earnings report
Check out this infographic breakdown of the company’s full-year performance, with highlights from its Innovative Medicine and MedTech businesses.
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy.
What are biologics?
Biologics, a class of medications derived from living organisms, treat a range of conditions including immune-mediated diseases and cancer. Learn how Johnson & Johnson is innovating in biologics to improve treatment options for people around the world.
Moving toward a more personalized approach to treating depression
The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.
“Our goal is a solution for every bladder cancer patient”
Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world.
Is this the end of one-size-fits-all treatments for depression?
Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.
Juvenile myasthenia gravis: Inside one adolescent’s journey
The condition is typically diagnosed in adults, but research suggests an uptick in adolescent patients. Learn more about the rare autoantibody disease, how one teen is managing it and why Johnson & Johnson is working to improve treatment options for patients of all ages.